Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.

Chunlin Chen, MD, PhD, John E Janik, MD, Karen Kaucic, MD, Lorin Roskos, PhD, Bahija Jallal, PhD, Gabriel J. Robbie, PhD

Blood (2009) 114 (22): 2670.

https://doi.org/10.1182/blood.V114.22.2670.2670

Published: 2009

Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Deirdre O’Mahony, MD, John C. Morris, MD, Maryalice Stetler-Stevenson, MD, Helen Matthews, RN, Stefania Pittaluga, MD, Paul Albert, PhD, Karen Kaucic, MD, Luz Hammershaimb, MD, Thomas A. Waldmann, MD, John E. Janik, MD

Blood (2007) 110 (11): 3565.

https://doi.org/10.1182/blood.V110.11.3565.3565

Published: 2007

Journal Articles

Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.

Bimalangshu R. Dey, MD, PhD, Andrew J. Yee, MD, Steven McAfee, MD, Christine Dube, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, Susan Saidman, PhD, Karen Malikowski, Frederic Preffer, PhD, Megan Sykes, MD, Thomas R. Spitzer, MD

Blood (2007) 110 (11): 5088.

https://doi.org/10.1182/blood.V110.11.5088.5088

Published: 2007

Journal Articles

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

Deborah A. Casale, MS, Nancy L. Bartlett, MD, David D. Hurd, MD, Francine Foss, MD, Barbara Pro, MD, Lubomir Sokol, MD, PhD, Ronald Lieberman, MD, Hammershaimb Luz, MD

Blood (2006) 108 (11): 2727.

https://doi.org/10.1182/blood.V108.11.2727.2727

Published: 2006

Journal Articles

Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes.

Scott A. Hammond, Stacy Fuhrmann, Shannon Roff, Peter A. Kiener, Steve Coats, Michael S. Kinch

Blood (2006) 108 (11): 2504.

https://doi.org/10.1182/blood.V108.11.2504.2504

Published: 2006

Journal Articles

Donor Specific Unresponsiveness Develops Following Loss of Chimerism in Recipients of Haploidentical Combined Bone Marrow/Kidney Transplantation but Not in Recipients of Bone Marrow Transplant Alone.

Giovanna Andreola, Juanita Shaffer, A. Benedict Cosimi, Tatsuo Kawai, Pete Cotter, Bimalangshu R. Dey, Nina Tolkoff-Rubin, Frederic I. Preffer, Susan Saidman, Kristin Kattleman, David H. Sachs, Thomas R. Spitzer, Megan Sykes

Blood (2006) 108 (11): 3103.

https://doi.org/10.1182/blood.V108.11.3103.3103

Published: 2006

Journal Articles

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Deirdre O’Mahony, MD, John C. Morris, MD, Leslie Moses, Diana O’Hagan, Wendy Gao, Maryalice Stetler-Stevenson, MD, Margaret Taylor, Luz Hammershaimb, MD, Thomas A. Waldmann, John E. Janik, MD

Blood (2005) 106 (11): 3353.

https://doi.org/10.1182/blood.V106.11.3353.3353

Published: 2005

Journal Articles

Fludarabine Treatment Is Associated with Depletion of Host CD4+CD25 high , FOXP3+, CTLA-4+ Cells and Increased Incidences of Full Donor Chimerism and GVHD in Non-Myeloablative Haploidentical Hematopoietic Cell Transplant Recipients.

Juanita M. Shaffer, Jean Villard, Terry Means, David Dombkowski, Bimalangshu Dey, Steven McAffee, Karen Ballen, Karen Power, Susan Saidman, Fredric Preffer, Thomas R. Spitzer, Megan Sykes

Blood (2005) 106 (11): 2898.

https://doi.org/10.1182/blood.V106.11.2898.2898

Published: 2005

Journal Articles

Minimal HLA Disparity and KIR Ligand Compatibility in Host Versus Graft Direction May Facilitate Donor Engraftment Following In Vivo and Ex Vivo T Cell Depleted (TCD) Nonmyeloablative Haploidentical Stem Cell Transplantation for Hematologic Malignancies.

Andrew J. Yee, MD, Thomas R. Spitzer, MD, Susan L. Saidman, PhD, Juanita Shaffer, Karen A. Power, Steven L. McAfee, MD, Karen K. Ballen, MD, Eyal C. Attar, MD, Frederic I. Preffer, PhD, Megan Sykes, MD, Bimalangshu R. Dey, MD

Blood (2005) 106 (11): 3668.

https://doi.org/10.1182/blood.V106.11.3668.3668

Published: 2005

Journal Articles

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Thomas R. Spitzer, MD, Steven L. McAfee, MD, Dey R. Bimalangshu, MD, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, PharmD, Fred Preffer, PhD, Susan Saidman, PhD, Juanita Shaffer, David H. Sachs, MD, Megan Sykes, MD

Blood (2005) 106 (11): 5431.

https://doi.org/10.1182/blood.V106.11.5431.5431

Published: 2005

Journal Articles

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507

Zhuo Zhang, Meili Zhang, Jeffrey V. Ravetch, Carolyn Goldman, Thomas A. Waldmann

Blood (2003) 102 (1): 284–288.

https://doi.org/10.1182/blood-2002-11-3601

Published: 2003

NARROW

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes.

Donor Specific Unresponsiveness Develops Following Loss of Chimerism in Recipients of Haploidentical Combined Bone Marrow/Kidney Transplantation but Not in Recipients of Bone Marrow Transplant Alone.

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Fludarabine Treatment Is Associated with Depletion of Host CD4+CD25 high , FOXP3+, CTLA-4+ Cells and Increased Incidences of Full Donor Chimerism and GVHD in Non-Myeloablative Haploidentical Hematopoietic Cell Transplant Recipients.

Minimal HLA Disparity and KIR Ligand Compatibility in Host Versus Graft Direction May Facilitate Donor Engraftment Following In Vivo and Ex Vivo T Cell Depleted (TCD) Nonmyeloablative Haploidentical Stem Cell Transplantation for Hematologic Malignancies.

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only